Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96%

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reports a regulatory notification of major holdings after a shareholder’s stake fell below a key threshold. The holder’s total voting rights decreased from 5.010000% to 4.960000%, representing 201,065,668 voting rights in GSK.

The position is split between ordinary shares and American Depositary Receipts (ADRs). Ordinary shares carry 88,816,040 indirect voting rights, equal to 2.190000% of voting rights, while ADRs carry 112,249,628 indirect voting rights, equal to 2.770000% of voting rights. No additional voting rights are held through financial instruments.

Key Figures

Resulting voting rights percentage: 4.960000% Previous voting rights percentage: 5.010000% Total voting rights held: 201,065,668 voting rights +2 more

5 metrics

Resulting voting rights percentage 4.960000% Total voting rights after threshold crossing

Previous voting rights percentage 5.010000% Position of previous notification

Total voting rights held 201,065,668 voting rights Resulting situation when threshold was crossed

Ordinary share voting rights 88,816,040 voting rights Indirect voting rights from ordinary shares, 2.190000%

ADR voting rights 112,249,628 voting rights Indirect voting rights from ADRs, 2.770000%

Key Terms

TR-1, voting rights, financial instruments, ADR, +2 more

6 terms

TR-1 regulatory

"TR-1: Standard form for notification of major holdings"

A TR-1 is a financial form used by investors to report significant ownership stakes in a company, typically when they acquire or dispose of a large number of shares. It helps keep the market informed about major shareholders and potential changes in control, allowing other investors to make better-informed decisions. This transparency encourages fair trading and reduces surprises related to ownership shifts.

voting rights financial

"Total number of voting rights held in issuer"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

financial instruments financial

"Financial Instruments according to (DTR5.3.1R.(1)"

Financial instruments are assets or contracts that hold monetary value and can be bought, sold, or traded. They serve as tools for investors to grow, protect, or transfer money, much like how a ticket or voucher can be used to access goods or services. These instruments help individuals and organizations manage financial goals and risks across different markets and economic conditions.

ADR financial

"ADRs US37733W2044 | | 112249628 | | 2.770000"

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

DTR5.1 regulatory

"Number of direct voting rights (DTR5.1)"

DTR5.2.1 regulatory

"Number of indirect voting rights (DTR5.2.1)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/29/2026 - 10:21 AM Accepted by SEC EDGAR 06/29/2026 - 10:20 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN7SWP63

Issuer Name

GSK PLC

UK or Non-UK Issuer

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Dodge & Cox

City of registered office (if applicable)

San Francisco

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

24-Jun-2026

6. Date on which Issuer notified

26-Jun-2026

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.960000	0.000000	4.960000	201065668
Position of previous notification (if applicable)	5.010000	0.000000	5.010000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
Ordinary GB00BN7SWP63		88816040		2.190000
ADRs US37733W2044		112249628		2.770000
Sub Total 8.A	201065668		4.960000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11. Additional Information

12. Date of Completion

26-Jun-2026

13. Place Of Completion

San Francisco, California, United States of America

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: June 29, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR

FAQ

What does this GSK (GSK) Form 6-K and TR-1 notification report?

It reports a change in a major shareholder’s voting stake in GSK. The filing shows the holder’s total voting rights fell to 4.960000%, triggering a mandatory disclosure under the UK’s major holdings rules.

How many GSK (GSK) voting rights does the shareholder now hold?

The shareholder now holds 201,065,668 voting rights in GSK. This corresponds to 4.960000% of the company’s voting rights, combining ordinary shares and American Depositary Receipts (ADRs) as disclosed in the notification.

How is the GSK (GSK) position split between ordinary shares and ADRs?

The position is split between ordinary shares and ADRs. Ordinary shares represent 88,816,040 indirect voting rights (2.190000%), while ADRs represent 112,249,628 indirect voting rights (2.770000%), together totaling 4.960000% of GSK’s voting rights.

Did the GSK (GSK) shareholder use financial instruments for additional voting rights?

No, the filing shows no voting rights held through financial instruments. Both sections 8.B1 and 8.B2 report no instruments, so the entire 4.960000% stake comes from ordinary shares and ADRs, without derivatives or similar arrangements.

What threshold change in GSK (GSK) voting rights triggered this disclosure?

The disclosure was triggered when the holding moved below an earlier 5.010000% position. The resulting situation shows 4.960000% of GSK’s voting rights, crossing a notifiable threshold under the applicable major holdings regulations.